Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

About this update from Cytokinetics, Incorporated

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten. Collectively, the new evidence expands understanding of the effectiveness of cardiac myosin inhibition with aficamten compared directly to metoprolol, a beta blocker, as well as specific safety and durability characteristics of MYQORZO across patient demographics, clinical, and economic subgroups. “The breadth of research being presented at ESC Heart Failure 2026 reflects our commitment to deepening the scientific understanding of oHCM and heart failure,” said Stephen Heitner, M.D., Senior Vice President, Clinical Research and Development, Cytokinetics. “These new insights underscore the strength and consistency of the clinical profile of MYQORZO, adding to the growing body of real-world evidence informing physician treatment decisions.” New Analyses Show MYQORZO Outperforms Metoprolol Across Sex and Doses A dose-dependent analysis from MAPLE-HCM compared aficamten to the beta-blocker metoprolol in patients with symptomatic oHCM. Key findings showed significant improvements in exercise capacity, outflow gradients, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) across all treatment doses. Conversely, metoprolol failed to show improvement in these outcomes regardless of the dose administered (Figure 1). Figure 1 A secondary analysis of sex differences in MAPLE-HCM showed consistent benefits of MYQORZO in women. Despite women entering the trial (42%) with more severe baseline characteristics, MYQORZO delivered nearly identical improvements in peak oxygen consumption (pVO2) for both sexes (+2.2 mL/kg/min). Both groups also saw significant gains in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and reductions in cardiac biomarkers and NT-proBNP. Long-term Data Reinforce Safety and Efficacy Profile of MYQORZO A prospective analysis of 122 ...

View stock analysis, news, and events for Cytokinetics, Incorporated